Marker Therapeutics Inc (NASDAQ:MRKR) — Market Cap & Net Worth
Market Cap & Net Worth: Marker Therapeutics Inc (MRKR)
Marker Therapeutics Inc (NASDAQ:MRKR) has a market capitalization of $18.67 Million ($18.67 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25419 globally and #5367 in its home market, demonstrating a -2.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Marker Therapeutics Inc's stock price $1.18 by its total outstanding shares 16673127 (16.67 Million). Also see Marker Therapeutics Inc total assets for a full breakdown of the balance sheet.
Marker Therapeutics Inc Market Cap History: 2015 to 2026
Marker Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $1.20 Billion to $19.67 Million (-31.48% CAGR). Also see MRKR operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Marker Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #718 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2349 of 3165 |
Weight: Marker Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Marker Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Marker Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Marker Therapeutics Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.00x
Marker Therapeutics Inc's market cap is 7.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $653.59 Million | $183.06K | -$10.98 Million | 3570.26x | N/A |
| 2018 | $925.36 Million | $205.99K | -$147.96 Million | 4492.16x | N/A |
| 2019 | $480.19 Million | $213.19K | -$21.43 Million | 2252.34x | N/A |
| 2020 | $241.76 Million | $466.79K | -$28.71 Million | 517.93x | N/A |
| 2021 | $158.43 Million | $1.24 Million | -$41.88 Million | 127.59x | N/A |
| 2022 | $44.33 Million | $3.51 Million | -$29.93 Million | 12.62x | N/A |
| 2023 | $91.70 Million | $3.31 Million | -$8.24 Million | 27.70x | N/A |
| 2024 | $51.85 Million | $6.59 Million | -$10.73 Million | 7.87x | N/A |
| 2025 | $24.84 Million | $3.55 Million | -$12.16 Million | 7.00x | N/A |
Competitor Companies of MRKR by Market Capitalization
Companies near Marker Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review MRKR intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Marker Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Marker Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Marker Therapeutics Inc's market cap moved from $1.20 Billion to $ 19.67 Million, with a yearly change of -31.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $19.67 Million | -20.81% |
| 2025 | $24.84 Million | -52.09% |
| 2024 | $51.85 Million | -43.45% |
| 2023 | $91.70 Million | +106.84% |
| 2022 | $44.33 Million | -72.02% |
| 2021 | $158.43 Million | -34.47% |
| 2020 | $241.76 Million | -49.65% |
| 2019 | $480.19 Million | -48.11% |
| 2018 | $925.36 Million | +41.58% |
| 2017 | $653.59 Million | +1.03% |
| 2016 | $646.92 Million | -46.11% |
| 2015 | $1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Marker Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.67 Million USD |
| MoneyControl | $18.67 Million USD |
| MarketWatch | $18.67 Million USD |
| marketcap.company | $18.67 Million USD |
| Reuters | $18.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-assoc… Read more